Available evidence indicates that the CD6 lymphocyte surface receptor is involved in T-cell developmental and activation processes, by facilitating cell-to-cell adhesive contacts with antigen-presenting cells and likely modulating T-cell receptor (TCR) signaling. Here, we show that in vitro activation of human T cells under different TCR-ligation conditions leads to surface downregulation of CD6 expression. This phenomenon was (i) concomitant to increased levels of soluble CD6 (sCD6) in culture supernatants, (ii) partially reverted by protease inhibitors, (iii) not associated to CD6 mRNA downregulation, and (iv) reversible by stimulus removal. CD6 down-modulation inversely correlated with the upregulation of CD25 in both lo/− T cells resulting from in vitro T-cell activation show higher apoptosis and lower proliferation levels than CD6 hi T cells, supporting the relevance of CD6 in the induction of proper T-cell proliferative responses and resistance to apoptosis. Accordingly, CD6 transfectants also showed higher viability when exposed to TCR-independent apoptosis-inducing conditions in comparison with untransfected cells. Taken together, these results provide insight into the origin of sCD6 and the previously reported circulating CD6-negative T-cell subset in humans, as well as into the functional consequences of CD6 down-modulation on ongoing T-cell responses, which includes sensitization to apoptotic events and attenuation of T-cell proliferative responses.
Available evidence indicates that the CD6 lymphocyte surface receptor is involved in T-cell developmental and activation processes, by facilitating cell-to-cell adhesive contacts with antigen-presenting cells and likely modulating T-cell receptor (TCR) signaling. Here, we show that in vitro activation of human T cells under different TCR-ligation conditions leads to surface downregulation of CD6 expression. This phenomenon was (i) concomitant to increased levels of soluble CD6 (sCD6) in culture supernatants, (ii) partially reverted by protease inhibitors, (iii) not associated to CD6 mRNA downregulation, and (iv) reversible by stimulus removal. CD6 down-modulation inversely correlated with the upregulation of CD25 in both inTrODUcTiOn Immune modulation is an active area of medical research for development of novel therapies that apply to immune-mediated disorders. Most promising targets are co-stimulatory (e.g., CD28) and-inhibitory (e.g., CTLA-4) immunoreceptors present at the immune synapse (IS)-the site of antigen-presenting cell (APC)-T-cell interaction that drives T-cell activation. CD6 is lymphocyte surface accessory molecule associating to the T-cell receptor (TCR) complex at the center of the IS (1), whose modulatory role (either positive or negative) in T-cell activation has not been definitively established, in part due to the lack of suitable genetically modified animal models. This contrasts with the identification of CD6 as a significant susceptibility locus for multiple sclerosis in genome-wide association studies (2) and the promising results of treating some autoimmune disorders with non-depleting anti-CD6 mAb (3) . CD6 is a 105-130 kDa glycoprotein expressed by all thymocytes and mature T cells, a subset of NK and B cells (4, 5) , and some hematopoietic cell precursors (6) , and brain areas (7) . It is composed of three scavenger receptor cysteine-rich (SRCR) extracellular domains, a transmembrane region and a cytoplasmic tail without intrinsic catalytic activity but harboring several motifs susceptible of phosphorylation and/or interaction with signal-transducing effectors (8) . Notably, CD6 plays a key role in the stabilization and maturation of the IS, as well in subsequent T-cell proliferative responses (9) (10) (11) . This is achieved through interaction of membrane-proximal SRCR domain (D3) of CD6 with the N-terminal domain (D1) of CD166/activated leukocyte cell adhesion molecule (ALCAM), a broadly distributed adhesion molecule of the Ig superfamily, expressed by dendritic cells (DC), macrophages, B cells, and thymic epithelial cells among others (12, 13) . The CD6 signaling pathway is only partially known and includes the activation of MAPK (14) , and recruitment of Syntenin-1 (15) and SH2 domain-containing leukocyte protein of 76 kDa (SLP-76) (16) . Recently, CD6 has been identified as a critical protein in the linker for the activation of T cells (LAT)-independent TCR signaling scaffold (17) .
Changes in CD6 surface levels have been reported under both physiologically and experimentally induced conditions, but their ultimate significance is not fully understood. In thymus, CD6 expression levels seem to be developmentally regulated as they increase when immature double-positive thymocytes are selected to a mature single-positive stage (18) . CD6 upregulation on both immature and mature thymocytes but not PBL is efficiently achieved via CD2 compared to CD3 cross-linking and correlates well with resistance to apoptosis, suggesting that CD6-dependent signals contribute to the positive selection and survival of thymocytes (18) . Protein kinase C (PKC) activators also positively upregulate CD6 expression on both peripheral T cells and thymocytes but only negligibly on lymphoblastoid B-cell lines (19) . Studies in herpes virus-infected patients showed a reduced expression of CD6, CD28, and CD5 on CD8 + T cells that expand after viral infection, while the CD4 + T cells maintained normal levels of these markers (20) . Interestingly, such a CD8 + T-cell population was more susceptible to both spontaneous and activation-induced cell death (AICD) (20) . An intriguing finding was also the discovery of a small subset of peripheral blood T cells from healthy subjects ( (21) . These CD6 lo/− T cells were reported as of unknown precursor origin and showed substantially reduced reactivity to allogeneic stimulation but not to mitogenic lectins (PHA) or soluble recall antigens (tetanus toxoid) (21) . Recently, it has been reported that human natural regulatory T cells (nTreg) are characterized by low/negative expression of CD6 (22) , and the authors hypothesized that it could be the same CD6
lo/− population identified by Rasmussen et al. (21) .
The existence of a soluble CD6 (sCD6) form of unknown origin and circulating at very low levels (pico/nano molar range) in sera from healthy individuals has also been reported (23) . Interestingly, elevated sCD6 levels were observed in patients suffering of primary Sjögren's syndrome (24) and systemic inflammatory response syndrome (25) , although a direct mechanistic and/or functional relationship between the two events is lacking.
The present study analyzes CD6 expression following different in vitro T-cell stimulatory conditions. The results reported herein indicate that CD6 is down-modulated in part due to proteolytic cleavage, and this contributes to homeostatic control of ongoing immune responses by making T cells more prone to apoptosis and less responsive to proliferative stimuli. − ) were generated as reported elsewhere (14, 26) . Unless otherwise indicated, cells were cultured in RPMI 1640 (Lonza) medium supplemented with 10% FBS (Gibco) and gentamicin (0.5 µg/mL, Braun).
MaTerials anD MeThODs

antibodies and reagents
The anti-CD6 161.8 (IgG1) and OX124 (IgG1) mAbs were kindly provided by Ramón Vilella (Immunology Department, Hospital Clínic, Barcelona) and Steven Cobbold (University of Oxford, Oxford, UK), respectively. Recombinant soluble human CD6 (rshCD6) and CD5 (rshCD5) were produced as previously reported (9, 23) . Staphylococcal enterotoxin B (SEB) was from Sigma.
Flow cytometry analyses and cell sorting
Human PBL were suspended in PBS containing 2% FBS for 30 min on ice and, then, stained with different combinations of fluorochrome-labeled mAb: CD6-FITC (M-T605), CD4-FITC (L200), CD45RA-PerCP-Cy™5.5 (HI100), and CD25-APC-H7 (M-A251) from BD Pharmingen; CD3-APC-Cy™7 (SP34-2), CD3-PE (UCHT1), CD25-V450 (M-A251), IgG1k-PE (MOPC-21), IgG1k-APC (MOPC-21), and CD197/CCR7-PE (3D12) from BD Biosciences; CD3-APC (MEM-57) and CD25-APC (MEM-181) from Immunotools; CD8-APC (HIT8a), CD8-Pacific Blue™ (SK1), CD27-Pacific Blue™ (M-T271), CD178/FasL-PE (NOK-1), and CD95/Fas-PerCP-Cy5. 5 T-cell stimulation assays PBL (10 5 cells/well) were cultured with PHA (5 µg/mL), anti-CD3 plus anti-CD28 (αCD3/CD28) dynabeads (2 μL/10 5 cells; Life Technologies), PMA (10 ng/mL; Sigma), or rhIL-2 (10 ng/mL; Roche) in X-VIVO™15 medium (Lonza) for 4 days at 37°C. In some experiments, at day 3 of culture, cells were stimulusdeprived and then re-stimulated with PHA (1 µg/mL) or left untouched for an additional 13-day period. Protease inhibitor TAPI-2 (100 mM; Sigma) or Complete™ (Roche) effects were tested on PHA-activated (2 µg/mL) PBL.
For T-cell proliferation assays, PBLs (10 5 cells/well) were labeled with CFSE and co-cultured with 2 × 10 3 SEB preloaded mature DCs (mDCs) from an unrelated donor and generated as described elsewhere (27) . In some experiments, at day 5, cells were analyzed for CD6 surface expression with biotinylated 161.8 mAb (2 µg/mL) plus Streptavidin (SAv)-Alexa Fluor ® 700 (Invitrogen). Percent of proliferating cells and number of cell cycles were determined by measuring the geometric mean of fluorescence intensity (Geo MFI) channel of CFSE lo and CFSE hi cells by flow cytometry and the FlowJo software.
Detection of scD6
ELISA detection of human sCD6 was performed on 96-well microtiter plates (Nunc, Roskilde, Denmark) coated overnight (o/n) at 4°C with PBL supernatants (SN) (100 µL). After blocking for 1 h at room temperature (RT) with PBS plus 3% BSA, biotinylated 161.8 mAb (2 µg/mL) was added and incubated for 2 h at RT. Bound mAb was detected by 1 h incubation at RT with SAv-Peroxidase (SAv-POD; Roche) and further color development by the addition of 3,3′,5,5′-tetramethylbenzidine liquid substrate (Sigma). Absorbance was measured at 450 nm with Epoch spectrophotometer (BioTek). For immunoprecipitation of sCD6, protein G sepharose beads (GE Healthcare Life Sciences) were coupled to 161.8 mAb following manufacturer's instructions and, then, incubated o/n at 4°C under orbital rotation with 1 mL SN from PHA-or rhIL-2-treated PBL. RshCD5 (500 ng) and rshCD6 (500 ng) were used as negative and positive controls, respectively. After washings, beads were eluted and run on 8% SDS-PAGE under reducing conditions for further Western blot analysis with rabbit anti-human CD6 antiserum (1:500) produced in our laboratory (27) , followed by HRP-labeled donkey anti-rabbit Igs (GE Healthcare Life Sciences). Chemiluminescence was developed with Supersignal West Dura Extended Duration Solution (Pierce, Rockford, IL, USA) and images were obtained using ImageQuant LAS 4000 (GE Healthcare Life Sciences).
Western Blot analysis
Cells were lysed after a 30 min incubation on ice with lysis buffer (10 mM Tris-HCl pH 7.6, 140 mM NaCl, 5 mM EDTA, 140 mM NaF, 0.4 orthovanadate, 5 mM pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor mixture tablets (Complete™), and 1% non-idet P-40). After centrifugation at 12,000 × g for 15 min at 4°C, Laemmli's buffer was added to 50 µL from cell lysates. Samples were boiled and run on 8% SDS-PAGE under reduction conditions for further WB analysis. Membranes were incubated with rabbit anti-human CD6 poAb (1:500), followed by anti-rabbit-HRP (1:2,500) (Roche). Chemiluminescence was developed with Supersignal West Dura Extended Duration Solution (Pierce, Rockford, IL, USA). Images were obtained using LAS 4000, and bands were quantified with Photoshop CS5 software.
Quantitative reverse Transcription Pcr (rT-qPcr) assays
Total RNA from non-treated or 24 h treated with rhIL-2 (10 ng/mL), PHA (5 µg/mL), or PMA (10 ng/mL) PBMC cells was obtained with PureLink RNA Mini Kit (Ambion, Life technologies) according to manufacturer's instructions. RNA was retrotranscribed into cDNA using the High capacity cDNA Reverse Transcription kit (Thermofisher). RT-qPCR was performed on an Applied Biosystems 7900 HT Fast Real Time PCR System using Taqman Fast universal PCR master Mix (Life Technologies/ThermoFisher) and CD6 specific TaqMan expression assays (Hs00198752_m1: exon boundary 1-2) and (Hs00945709_m1: exon boundary 5-6) (ThermoFisher Scientific). Results in triplicates were normalized to gycleraldehyde-3-phosphate dehydrogenase (GAPDH, Hs99999905_m1), using the 2ΔCt formula, where ΔCt = Ct (GADPH) − Ct (gene of interest). Results are represented as relative values.
cytotoxicity assays
Parental and CD6-transfected 2G5 cells were treated with different concentrations of doxorubicin (0.1-10 µM, Pfizer), PHA (2 µg/mL), or puromycin (0.25-2.5 µg/mL) for 24-48 h at 37°C in culture medium and, then, analyzed by flow cytometry for apoptosis cell detection with Annexin V-FITC or Annexin V-PE and 7-AAD.
statistical analyses
Data are expressed as the mean ± SD or SEM using GraphPad software. Significant differences between two groups were determined by using unpaired Student's t-test and between three or more groups with one-way ANOVA followed by Tukey's test. resUlTs cD6 surface expression is Downregulated following T-cell activation CD6 is highly expressed on major human T-cell subsets (CD3
+ and CD3
) from resting PBLs (Figures 1A-C) . However, following TCR-mediated activation with either PHA (5 µg/mL) or anti-CD3 plus anti-CD28 beads (αCD3/CD28) a significant and sustained reduction of CD6 surface levels was observed in both peripheral T-cell subsets compared to unstimulated cells cultured in the presence of rhIL-2 (Figures 1A-C). As expected from previous reports (18), CD6 expression was upregulated by PMA (10 ng/mL), a potent polyclonal T-cell activator overcoming the need for TCR-ligation ( Figures 1A,B) . Since the T-cell activating agents used above (PHA, PMA, and αCD3/CD28) might result in supra-physiological responses, changes in CD6 surface expression were analyzed following a more physiological cell contact-dependent TCR stimulation system. To this end, CFSE-labeled PBL was co-cultured for 5 days with SEB pre-loaded allogeneic mDCs and proliferating (CFSE lo ) and non-proliferating (CFSE hi ) cells were analyzed for CD6 expression. As illustrated by Figure 1D , CFSE lo cells showed a significant reduction of CD6 expression, as measured by Geo MFI, compared to CFSE hi cells. These results support the notion that CD6 downregulation is an integral late event of TCR-mediated T-cell activation. Furthermore, CD6 downregulation was specific since the expression of CD5, a closely related lymphoid receptor partly associating with CD6 (28), was upregulated under the same stimulatory conditions ( Figure S1 in Supplementary Material), according to previously reported data (29) .
cD6 expression inversely correlates with cD25 expression following T-cell activation regardless of FoxP3 induction
To further confirm that downregulated CD6 expression was linked to T-cell activation, PBLs were double stained for CD25 and CD6 expression at different time points following stimulation with αCD3/CD28 beads, PHA (2 μg/mL) or rhIL-2 (10 ng/mL).
As shown in Figures 2A-C, both CD4
+ and CD8 + T cells increased their CD25 expression post-stimulation with αCD3/ CD28 or PHA and concomitantly decreased that of CD6 at later time points (96 h in the represented case). It is noteworthy that CD6 down-modulation could be detected at even earlier time points depending on the donor and the use of high PHA doses (5 µg/mL) ( Figure S2 in Supplementary Material). (Figure 3A) , according to our in vitro data. Similar studies were then extended to other peripheral T-cell populations related to signal strength and/or extent during T-cell activation events, namely central [central memory T cell (TCM)] and effector [effector memory T cell (TEM), TEMRA] memory cells (30, 31) . As shown in Figures 3B,C, significant lower CD6 surface expression levels were observed in TEM and TEMRA cells from both CD4
+ and CD8 + compartments compared to naïve and TCM cells. Within TEM and TEMRA populations, the lowest CD6 surface levels were observed among the late subset, which expresses low/negative levels of CD27 (CD27 lo/− ) ( Figures 3B,C) , a co-stimulatory molecule of the TNFR family involved in the maintenance of proliferative capabilities of activated T cells and the generation of T-cell memory (32) . Taken together, these results support that CD6 downregulation also occurs in vivo in the context of activation-related phenomena and effector memory T-cell generation.
cD6 Down-Modulation is Dependent on intracellular ca 2+ influx
To get some mechanistic insight into CD6 down-modulation, the effect of different pharmacological agents was explored. As shown in Figure 4A , ionomycin (0.7 µg/mL) either alone or in combination with PMA (10 ng/mL) down-modulated surface CD6 expression to a similar extent than induced by PHA (5 µg/mL), indicating that Ca 2+ influx-dependent events are involved in CD6 down-modulation. These data, together with the fact that PMA stimulation increased CD6 expression, implies that PKC does not play a relevant role in CD6 downregulation. Finally, the selective inhibitor of MAP kinase kinases (MEK1/2) U0126 was unable to reverse the effects of PHA stimulation (Figure 4A) , arguing also against a relevant contribution of the MAPK pathway in the down-modulation of surface CD6 expression.
cD6 Down-Modulation Does not involve changes in cD6 isoform Utilization or mrna levels T-cell activation has been reported to upregulate the expression of an alternatively spliced CD6 extracellular isoform (CD6ΔD3) lacking the CD166/ALCAM-binding domain (D3) (33) . To explore this possibility as a temptative cause for CD6 down-modulation, PBLs were stained with different anti-CD6 mAbs at different time points post-PHA stimulation. As illustrated in Figure 4B ( Figure S2 in Supplementary Material), the downregulated CD6 expression was detectable by the 161.8 mAb (14) but also the non-overlapping M-T605 (recognizing the amino-terminal D1 domain) (11) and OX124 (recognizing the CD166/ALCAMbinding D3 domain) mAbs (10) in a time-and dose-depending manner. This would indicate that CD6 down-modulation involves reduced surface expression of full-length and/or D3-deficient (CD6ΔD3) isoforms.
Next, putative changes in CD6 mRNA expression levels following T-cell activation were further assessed by RT-qPCR using probes specific for the exon 1-2 boundary (present in all reported CD6 isoforms) or the exon 5-6 boundary (absent from CD6ΔD3 isoforms). As illustrated in Figure 4C , PMA increased the levels of CD6 mRNA while both PHA and rhIL-2 did not induce significant changes. This would argue against reduced CD6 transcription as a cause of surface CD6 down-modulation following T-cell activation.
scD6 is released following T-cell activation
Next, it was explored whether the decreased surface CD6 expression could result from proteolytic cleavage of the membrane-bound form as previously reported for CD5 (34) . The ELISA analysis of culture SN from PBLs stimulated with αCD3/CD28 (Figure 5A ) or PHA (Figures 5C,D) showed significant increased levels of sCD6 from day 2 compared with cells exposed to rhIL-2. Western blot analysis of CD6 immunoprecipitates from αCD3/CD28-activated cell SN rendered a CD6-reactive band with similar molecular mass (~70 kDa) to rshCD6 used as a positive control (Figure 5B) . Reactivity was not observed in immunoprecipitates from rhIL-2 treated SN or from recombinant rhsCD5 (Figure 5B) . The addition of a protease inhibitor cocktail (Complete™) significantly reduced, though incompletely, both the release of sCD6 and the surface CD6 down-modulation ( Figure 5C ) from activated PBLs. Similar results were obtained using TAPI-2 ( Figure 5C ), a broad metalloproteinase inhibitor (35) with relative specificity for TNF-α-converting enzyme (TACE; also named ADAM17), an enzyme involved in the shedding of several surface proteins including the CD6 ligand (CD166/ALCAM) (36) . No differences in cell viability were detected at the end of the stimulation period among all the samples analyzed (data not shown). Altogether, these results suggest that activation-induced surface CD6 down-modulation may result, at least in part, from proteolytic release involving members of the ADAM (a disintegrin and metalloproteinase) family. FigUre 4 | CD6 down-modulation is dependent on Ca 2+ influx and does not involve differential utilization of extracellular CD6 isoforms nor changes in CD6 mRNA levels. (a) PBL (2 × 10 5 /well) was cultured for 2 (left) or 4 (right) days in the presence of rhIL-2 (10 ng/mL) alone, or together with PMA (10 ng/mL), PMA (10 ng/mL) plus Ionomycin (0.7 µg/mL), Ionomycin (0.7 µg/mL), PHA (5 µg/mL), and PHA plus U0126 (10 µM). Cells were stained with labeled mAb for CD3 (UCTH1) and CD6 (M-T605) and analyzed by flow cytometry. Shown is a bar chart representing the mean ± SD of geometric mean of fluorescence intensity (Geo MFI) values for CD6 expression. The putative reversibility of PHA-induced CD6 downregulation on CD4 + T cell was next investigated by analyzing CD6 and CD25 expressions upon re-stimulation with PHA, PHA deprivation (by extensive washing), or left untouched for an additional period of time ( Figure 5D ). PHA-deprived cells gradually recovered CD6 expression over time, while it stayed low for PHA re-stimulated cells. In a similar manner, CD25 expression level gradually decreased once the cells were PHA deprived or left untouched, while it remained high upon PHA re-stimulation. Accordingly, sCD6 levels in culture SNs slowly declined unless cells were restimulated ( Figure 5D, right hand side) . This indicates that CD6 Western blot analysis of whole cell extracts from PBLs stimulated or not with αCD3/CD28 revealed two CD6-reactive bands of ~115 and ~75 kDa (Figures 5E-G) , likely corresponding to fully processed membrane-bound and unprocessed intracellular forms, respectively (37) . While the intensity of the ~75 kDa band remained mostly unchanged over time, there was a drop in the intensity of the ~115 kDa band at day 2 post-αCD3/CD28 stimulation that recovered by day 6 (Figures 5E-G) . This result mimics the above reported kinetic analysis of surface CD6 expression ( Figure 5D ) and supports the assumption that the ~115 kDa band corresponds to membrane-bound CD6.
cD6 Downregulation correlates with increased susceptibility to apoptosis
The functional significance of CD6 down-modulation upon T-cell activation was further explored by analyzing the number of live/apoptotic cells, as well as the expression of surface markers from the TNF superfamily (CD27, CD95/Fas, and CD178/FasL) on CD6
+ versus CD6 lo/− activated T cells (CD3 + CD25 + ). As illustrated by Figure 6A, 3 (38) involved in resistance to apoptosis (Figure 6B) . In contrast, the CD25 + CD6 lo/− cells expressed significant higher surface levels of the AICD markers CD95/Fas and CD178/FasL than CD25 +
CD6
+ cells (Figure 6C ). These results suggest that reduction of CD6 surface levels correlates with a reduced T-cell viability and with markers of increased sensibility to apoptosis.
As PMA-induced activation upregulates CD6 expression, we also compared the apoptosis levels among PMA-activated T cells expressing different CD6 surface levels. The analysis of cell viability by annexin V and 7-AAD criteria indeed showed a higher frequency of viable cells among PMA-stimulated PBMC with higher CD6 surface levels compared with those expressing lower ones (Figure 6D) . Thus, higher CD6 upregulation also correlates with higher viability among PMA-stimulated cells. 
Modulation of cD6 expression influences the survival of leukemic T cells
The protective effect of CD6 expression on TCR-induced apoptosis would agree with previous reports showing that CD6 ligation prevents IgM cross-linking-induced apoptosis of leukemic B cells (chronic lymphocytic leukemia) (39) . It was then investigated whether surface CD6 expression influences apoptosis induced by genotoxic agents overcoming the need of signaling via TCR.
To that end, we used untransfected and CD6-transfected 2G5 cells, a CD6-deficient Jurkat T-cell derivative (14, 26) ( Figure 8A ). As shown in Figure 8B , 2G5 cell transfectants underwent down-modulation of CD6 surface expression by days 1 and 2 post-PHA activation, in a similar manner to that observed for peripheral T cells. Furthermore, CD6-transfected 2G5 cells were consistently more resistant to apoptosis induced by doxorubicin (0.1-10 µM) or puromycin (0.25-2.5 µg/mL) than parental (untransfected) cells ( Figure 8C ). These data support the notion that CD6 rescues lymphocytes from apoptosis induced also by TCR-independent pathways.
DiscUssiOn
The current view is that CD6-through its interaction with CD166/ALCAM-is involved in positive selection and survival of developing mouse thymocytes (18, 40) , as well as in early adhesive APC-T-cell contacts driving to formation of mature IS and further proliferative responses of human T cells (9) (10) (11) .
In the present work, evidence is provided on the involvement of CD6 down-modulation in the regulation of late human T-cell activation events, rendering cells hyper-sensitive to apoptosis and hypo-responsive to further proliferative stimulation. Surface downregulation of CD6 was observed on resting human T cells upon in vitro activation with different TCR-dependent stimuli (PHA, αCD3/CD28, and SEB-loaded allogeneic mDC), which in turn upregulated CD25 expression. These activationinduced T-cell changes were reversible since expression of both CD6 and CD25 recovered upon stimulus removal. Interestingly, CD6 downregulation was observed in CD25 + T cells independently of FoxP3 co-expression. Consequently, CD6 was found downregulated on T cells with both activated and regulatory phenotypes, thus arguing against being a characteristic exclusive of human Treg as recently proposed (22) . Thus, CD6 downregulation would depend on T-cell activation signals irrespective of the differentiation pathway (effector or regulatory) that the cell undergoes.
The in vivo occurrence of a small proportion of circulating T cells from healthy individuals with downregulated CD6 surface expression and diminished alloreactivity was reported some time ago (21) , although their origin could not be determined. The ex vivo analysis presented here demonstrates the expression of lower CD6 surface levels on CD25 + T cells from healthy donors compared to their CD25 − counterparts. In addition, TEM and TEMRA subsets from both the CD4 + and CD8 + compartments expressed significantly reduced CD6 surface levels compared to naïve and TCM-cell populations. These data indicate that CD6 downregulation also occurs in vivo in the context of activationrelated phenomena such as generation of effector memory cells (TEM and TEMRA) and are in agreement with a signal strength/ duration-dependent and progressive model by which a naïve T-cell progresses to TCM and then to TEM/TEMRA (31, 41) .
Different mechanisms by which CD6 functional capabilities would be severely afflicted upon lymphocyte activation-related events have already been reported. Mitogen-activated PBL is known to express no less than five different alternatively spliced CD6 cytoplamic isoforms involving loss of structural motifs relevant to signal-transducing function (42, 43) . Likewise, the extracellular isoform (CD6Δ3) lacking the CD166/ALCAMbinding domain (D3) of CD6-and consequently unable to localize at the APC-T-cell interface during IS formation-is upre gulated and dominates upon T-cell activation (33) . The present report shows shedding of membrane-bound CD6 as an additional mechanism previously suspected but unproven (24, 25) . However, we cannot exclude other alternative and/or complementary mechanism contributing to CD6 down-modulation, as it is the case of internalization via coated pits or c-Cblmediated ubiquitination previously reported for CD5 (44) (45) (46) . The surface receptor levels are often regulated by endocytosis and subsequent lysosomal degradation or recycling to plasma membrane, depending on whether they are ubiquitinated or not. The Cbl family of ubiquitin ligases is highly expressed in T cells and deeply involved in negative regulation of T-cell activation. Available evidence points to the role of Cbl ligases in regulating the surface levels of CD5 (44, 47) , and this could also apply to the sister molecule CD6. Thus, T-cell activation could contribute to reduced CD6 surface levels by both proteolytic events and Cbl-mediated ubiquitination, which could be direct or indirect through its physical association with CD5. Regarding the putative contribution of alternative splicing to membrane-bound CD6 down-modulation, available reports by independent groups (33, 42, 43) have not identified alternatively spliced mRNAs coding for sCD6 and/or CD6 isoforms devoid of its entire extracellular region.
The present data indicate that CD6 shedding is due to proteolytic cleavage by, at least in part, members of the ADAM family of metalloproteinases. TACE/ADAM17 is known to generate soluble forms of several lymphocyte surface receptors (e.g., CD62L, CD16, CD166/ALCAM, ICOS ligand, and FasL) in the context of cell activation (36, (48) (49) (50) (51) and would be a feasible candidate. However, the fact that CD6 down-modulation was induced by ionomycin but not by PMA (Figure 4A ) would favor the putative involvement of ADAM10, as reported for other transmembrane receptors (52) .
The functional role of sCD6 release in T-cell physiology is uncertain. Available in vitro evidence shows that sCD6 interferes with T-cell activation and IS maturation (1, 9, 10) . Based on this, it can be speculated that sCD6 would act as a "decoy receptor" contributing to the inactivation of bystander T cells at inflammation sites. In any case, the data collectively point to the existence of different levels of the regulation of human CD6 function during late T-cell activation, all of them involving physical loss of relevant extracellular and/or intracytoplasmic regions. Figures S4A,B in Supplementary Material), thus stressing the existence of interspecies differences. Nevertheless, the modulation of mouse CD6 function by mechanisms other than surface downregulation (e.g., expression of alternatively spliced extracellular and/or intracytoplasmic isoforms) is still possible and would deserve further investigation.
The functional consequences of human CD6 downregulation reported here are (i) impaired T-cell proliferative capabilities and (ii) higher susceptibility to apoptosis (namely AICD), as deduced from the analysis of in vitro-generated and sorted CD25 
CD6
hi counterparts. This agrees with the critical role assigned to CD6-CD166/ALCAM interaction for IS formation and maturation (9-11) as well as for TCR signaling (17) . The higher levels of apoptotic cells and of AICD markers (CD95/Fas and CD178/FasL) in CD25
+ CD6 low/− T cells also agree with the anti-apoptotic properties assigned to CD6 (39) . Ligation of CD6 on T cells by specific mAbs or CD166/ALCAM activates the MAPK cascade (14) , which is known to result in higher levels of mcl-1 and promotion of cell survival (53) . A similar mechanism would apply for the modulation of bcl-2/Bax equilibrium observed in B cells following IgM-induced apoptosis (39) . The positive effect of CD6 in T-cell survival and proliferation would not be restricted to humans as CD6-deficient mouse T cells also exhibit a limited proliferation and increased apoptosis following in vitro activation (54) . The intriguing fact is that the anti-apoptotic effect of CD6 is not necessarily linked to TCR cross-linking, since it is also evidenced upon corticosteroid (39), Galectin-1 and -3 (27) , and as shown here, genotoxic-induced apoptosis, which all by-pass such a relevant lymphocyte receptor complex. Indeed, the sole presence of CD6 was sufficient to reduce the deleterious effects of doxorubicin or puromycin in leukemic Jurkat T cells. These results not only confirm the TCR-independent anti-apoptotic properties of CD6 but also open the possibility of sensitizing CD6-positive leukemic T cells to increase the efficacy and/or reduce the toxicity of chemotherapeutic agents as recently proposed (55) .
Altogether, the present report provides new insight into the origin of sCD6 and the circulating CD6 − T-cell subset reported long ago (21, 24) , as well as into the functional consequences of CD6 down-modulation on ongoing T-lymphocyte responses. The observed effects on the attenuation of T-cell proliferative responses and sensitization to apoptotic events place CD6 as a new player in T-cell homeostatic processes.
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